ES2052368T3 - Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. - Google Patents
Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.Info
- Publication number
- ES2052368T3 ES2052368T3 ES91903050T ES91903050T ES2052368T3 ES 2052368 T3 ES2052368 T3 ES 2052368T3 ES 91903050 T ES91903050 T ES 91903050T ES 91903050 T ES91903050 T ES 91903050T ES 2052368 T3 ES2052368 T3 ES 2052368T3
- Authority
- ES
- Spain
- Prior art keywords
- recombination
- factors
- well
- expression
- viruses used
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE DESCRIBEN FACTORES SANGUINEOS PRODUCIDOS DE FORMA RECOMBINANTE ASICOMO UN PROCESO PARA SU PREPARACION, DICHOS FACTORES SANGUINEOS TIENEN UNA PROPORCION DE FORMA BIOLOGICAMENTE ACTIVA CON RELACION A LA FORMA ANTIGENICA DE AL MENOS EL 50%, PREFERIBLEMENTE EN EL RANGO DE ENTRE EL 60 Y 90%. SE PRESENTAN UNOS VIRUS RECOMBINANTES PARA UNA VACUNA USADOS EN EL MENCIONADO PROCESO. EL PROCESO DE ACUERDO CON ESTA INVENCION SUMINISTRA UN SISTEMA DE EXPRESION MEJORADO CON UNA ALTA CAPACIDAD POST TRANSLACIONAL BAJO CONDICIONES DE EXPRESION ESTABLES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP90101623 | 1990-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2052368T3 true ES2052368T3 (es) | 1994-07-01 |
Family
ID=8203546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91903050T Expired - Lifetime ES2052368T3 (es) | 1990-01-26 | 1991-01-24 | Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0512011B1 (es) |
JP (1) | JP2549224B2 (es) |
AT (1) | ATE103982T1 (es) |
CA (1) | CA2073859A1 (es) |
CS (1) | CS17291A2 (es) |
DE (2) | DE69101634T4 (es) |
DK (1) | DK0512011T3 (es) |
ES (1) | ES2052368T3 (es) |
FI (1) | FI923347A (es) |
HU (1) | HUT63459A (es) |
NO (1) | NO922953L (es) |
WO (1) | WO1991011519A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69229390T2 (de) * | 1991-08-26 | 1999-11-11 | Immuno Ag, Wien | Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus |
DE69229126T2 (de) * | 1991-12-31 | 1999-12-30 | Zymogenetics, Inc. | Verfahren zur Herstellung von Thrombin |
US5527692A (en) * | 1991-12-31 | 1996-06-18 | Zymogenetics, Inc. | Methods for producing thrombin |
US7060484B1 (en) | 1993-11-12 | 2006-06-13 | Gilead Sciences, Inc. | Polypeptides and coagulation therapy |
CN1103815C (zh) * | 1993-11-12 | 2003-03-26 | 吉里德科学公司 | 凝血酶突变体 |
DE4430204A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
AT403167B (de) * | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
AT404357B (de) * | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
EP1136553A1 (en) * | 2000-03-22 | 2001-09-26 | Octagene GmbH | Production of recombinant blood clotting factors in human cell lines |
AU5471501A (en) * | 2000-03-22 | 2001-10-03 | Octagene Gmbh | Production of recombinant blood clotting factors in human cell lines |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
AU2003221469A1 (en) | 2002-04-30 | 2003-11-17 | Bayer Healthcare Llc | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
AU2004221761B2 (en) | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
NZ573412A (en) | 2003-06-19 | 2010-09-30 | Maxygen Holdings Ltd | Factor VII or VIIa Gla domain variants |
JP6245299B2 (ja) * | 2016-04-27 | 2017-12-13 | バクスアルタ ゲーエムベーハー | 組換え安定細胞クローン、その産生およびその使用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
EP0289586A4 (en) * | 1986-11-17 | 1990-04-10 | New England Medical Ct | INCREASING GAMMA CARBOXYLATION OF RECOMBINANT, VITAMIN K-DEPENDENT PROTEINS. |
JPH03501921A (ja) * | 1987-05-18 | 1991-05-09 | インテグレイテッド・ジェネティクス・インク | 改良タンパク質分子、並びにその製造及び活性化方法 |
FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
DE3813093A1 (de) * | 1988-04-19 | 1989-11-09 | Immuno Ag | Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung |
FR2638643B1 (fr) * | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
-
1991
- 1991-01-24 EP EP91903050A patent/EP0512011B1/en not_active Expired - Lifetime
- 1991-01-24 WO PCT/EP1991/000139 patent/WO1991011519A1/en active IP Right Grant
- 1991-01-24 CA CA002073859A patent/CA2073859A1/en not_active Abandoned
- 1991-01-24 ES ES91903050T patent/ES2052368T3/es not_active Expired - Lifetime
- 1991-01-24 DE DE69101634T patent/DE69101634T4/de not_active Expired - Lifetime
- 1991-01-24 JP JP3503086A patent/JP2549224B2/ja not_active Expired - Lifetime
- 1991-01-24 DE DE91903050A patent/DE69101634D1/de not_active Expired - Fee Related
- 1991-01-24 AT AT91903050T patent/ATE103982T1/de not_active IP Right Cessation
- 1991-01-24 HU HU922435A patent/HUT63459A/hu unknown
- 1991-01-24 DK DK91903050.2T patent/DK0512011T3/da active
- 1991-01-25 CS CS91172A patent/CS17291A2/cs unknown
-
1992
- 1992-07-23 FI FI923347A patent/FI923347A/fi not_active Application Discontinuation
- 1992-07-24 NO NO92922953A patent/NO922953L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1991011519A1 (en) | 1991-08-08 |
DE69101634D1 (de) | 1994-05-11 |
NO922953D0 (no) | 1992-07-24 |
FI923347A0 (fi) | 1992-07-23 |
DE69101634T4 (de) | 1994-12-01 |
NO922953L (no) | 1992-09-04 |
EP0512011A1 (en) | 1992-11-11 |
JP2549224B2 (ja) | 1996-10-30 |
CS17291A2 (en) | 1991-09-15 |
ATE103982T1 (de) | 1994-04-15 |
DE69101634T2 (de) | 1994-08-18 |
FI923347A (fi) | 1992-07-23 |
HU9202435D0 (en) | 1992-10-28 |
EP0512011B1 (en) | 1994-04-06 |
HUT63459A (en) | 1993-08-30 |
JPH05507401A (ja) | 1993-10-28 |
DK0512011T3 (da) | 1994-05-09 |
CA2073859A1 (en) | 1991-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2052368T3 (es) | Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. | |
ES2092183T3 (es) | Procedimiento para la preparacion de poli(tereftalato de butileno) a partir de residuos de poli(tereftalato de etileno). | |
SE8300623D0 (sv) | Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin) | |
ES2059565T3 (es) | Virus mva de la vacuna, recombinante. | |
ES2089316T3 (es) | Agente viral asociado con la enfermedad porcina misteriosa (mystery swine desease). | |
ES2078255T3 (es) | Regiones inmunogenas en la proteina e-7 del papilomavirus humano tipo 16. | |
ATE33503T1 (de) | Pharmazeutische und tiermedizinische praeparate von interleukin-2, in dem cystein-125 ausgetauscht worden ist (muteine), sowie deren herstellung. | |
KR910003102A (ko) | 사람 에리트로포이에틴의 뮤테인 | |
ES2152998T3 (es) | Agente anticomplementario obtenido a partir de fucanos de algas pardas. | |
BR9814473A (pt) | Imunógenos anti-retrovirais, preparação e uso | |
ES2035818T3 (es) | Mutantes de delecion de la timidin-kinasa del virus del herpes bovino-1, vacunas contra la rinotraqueitis bovina infecciosa que los contienen y metodos para su produccion y uso. | |
ES2126620T3 (es) | Retrovirus del grupo de los vih y su utilizacion. | |
DE68903846D1 (de) | Neue galenische form von fenofibrat. | |
ES2121000T3 (es) | Composicion utilizada como agente terapeutico contra enfermedades hepaticas virales cronicas. | |
ES2134197T3 (es) | Vacunas contra el virus del herpes simplex vp16. | |
IL106968A0 (en) | Potentiation of immunogenic response | |
CO4650186A1 (es) | Composicion de vacuna | |
ES2075378T3 (es) | Procedimiento para la preparacion del factor viii humano y de analogos del factor viii. | |
ATE265535T1 (de) | Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen | |
ES2220256T1 (es) | Albumina humana terapeutica con baja actividad para la fijacion de aluminio. | |
PT91316A (pt) | Processo para a preparacao de vectores recombinantes e de particulas hbsag recombinantes hibridas tendo as caracteristicas morfologicas do antigenio hbsag contendo uma sequencia imunogenica que induz anticorpos neutralizantes dirigidos contra hiv ou susceptivel de ser reconhecida por tais anticorpos | |
ES2079851T3 (es) | Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas. | |
ES2062990T3 (es) | Vacunas, que contienen la proteina f del virus del sida. | |
NO881661D0 (no) | Humane rhinoviruspeptider. | |
ES2052273T3 (es) | Composicion que contiene un epitopo b de la glicoproteina que envuelve un retrovirus y un epitopo t de una proteina distinta de dicho retrovirus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 512011 Country of ref document: ES |